October 10th 2025
The increasing diversity and complexity of injectable drug products is driving innovation.
EC Approves Bristol Myers Squibb’s Opdivo in Second-Line Treatment of Esophageal Cancer
November 24th 2020The EC’s approval was based on positive results from a Phase III clinical trial that demonstrated a statistically significant and clinically meaningful improvement in patients compared to chemotherapy.